登录/注册我是招聘方 免费发布职位
Senior Data Engineer - Contrac
16-27K/月北京市-北京/本科及以上/5-10年
丁鑫科一周前来过
江西亚麦嘉企业管理有限公司

职位详情

岗位职责

任职要求:
Bachelor’s or Master’s degree in Computer Science, Engineering, Data Science, or related field. ​
8+ years of handson experience designing and building data pipelines and infrastructure. ​
Strong proficiency in data engineering tools and technologies, such as Apache Spark, Hadoop, Kafka, and cloud-based platforms (AWS, Azure, or GCP).
Hands-on experience with data modeling, ETL processes, and distributed data processing frameworks.
Proficiency in programming languages like Python, R, Java, and expertise in SQL.
Solid understanding of data architecture principles, microservices, and data governance frameworks. Excellent problem-solving skills and ability to drive solutions in a fast-paced environment.
Strong communication and collaboration skills, with a proven ability to work with both technical and non-technical stakeholders.
岗位职责:
Architect, implement, and optimize ETL/ELT workflows using tools such as Databricks and Informatica to ingest and process large datasets.
Deploy and manage data infrastructure on Azure and AWS, including containerized services and serverless components.
Partner with data scientists, software engineers, and business stakeholders to translate requirements into scalable data solutions.
Monitor and tune pipeline performance, implement robust monitoring/alerting (e.g., Prometheus, DataDog), and troubleshoot production issues.
Define and enforce data validation rules, lineage tracking, and governance standards to ensure accurate and compliant data usage.
Build CI/CD pipelines for data code, automate deployments, and support model operationalization workflows.
Share knowledge of data engineering best practices, conduct code reviews, and mentor junior engineers. ​

任职要求

工作地点

    建国路环贸
复制

公司信息

某医药公司

  • 上海
  • 1000-9999人
  • 生物技术
  • 民营
  • 不需要融资
百济神州是一家植根中国的全球性商业化生物医药公司,致力于成为分子靶向药物和免疫肿瘤药物研发,及商业创新领域的全球领导者。 2017年,百济神州与新基公司达成战略合作伙伴关系,向新基转让了tislelizumab在美国、欧洲、日本和亚洲以外的其他地区的实体瘤开发和商业化的独家权益,保留了在亚洲(除日本外)开发和商业化tislelizumab用于治疗实体瘤的权益,以及用于治疗恶性血液肿瘤和进行内部组合疗法的全球范围权益。 此外,百济神州获得了新基公司在华获批药物——注射用白蛋白紫杉醇(ABRAXANE?), 瑞复美(REVLIMID?)和 维达莎(VIDAZA?)的独家授权,并接管其在华商业运营团队。 2018年1月,百济与Mirati公司sitravatinib在亚太地区的独家授权协议,进一步拓宽了公司的产品组合。 截至目前,百济神州在全球各地拥有超过1100名员工,其中包括在中国、美国、澳大利亚和瑞士的超过650名科学家及临床医学专家。 公司在中国的北京、上海、美国的马萨诸塞州Cambridge,新泽西州Fort Lee和加利福尼亚州旧金山Emeryville和San Mateo,瑞士的巴塞尔均设有办事机构。除此之外,百济神州在中国大陆还拥有位于北京的研发中心,苏州、广州两大生产基地,以及在上海的商业运营中心。
公司热招职位查看全部职位
code